Shanghai Junshi Biosciences Co., Ltd. (01877) announced that Toripalimab for the treatment of soft tissue sarcoma has recently been granted the orphan-drug designation by the US Food and Drug Administration (the FDA), which is the third orphan-drug designation obtained by Toripalimab.
Toripalimab for the treatment of mucosal melanoma and nasopharyngeal carcinoma were previously granted the orphan-drug designation by the FDA.